A Phase 1, Randomized, 4-Way Crossover Study to Evaluate the Effect of Varying Bonding Strength Between Active and Inactive Layers on Adhesion of the Corplex™ Donepezil Transdermal Delivery System in Healthy Volunteers

Corium Inc.0 个研究点目标入组 36 人开始时间: 2020年2月20日最近更新: 2021年6月7日

适应症

试验速览

阶段: 1 期
状态: 撤回
发起方: Corium Inc.
入组人数: 36

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment
盲法: Blinded (masking used)

入排标准

年龄范围: 18 Years 至 o limit（—）
性别: All

入选标准

•Key inclusion criteria include:
•1.Healthy, adult, male or female, at least 18 years of age at Screening,
•2.Nonsmoker or occasional smoker (less than or equal to 1 cigarette or equivalent/day) must agree not to smoke or agree to consume no more than 1 cigarette or equivalent/day from the Screening Visit until after the End of Study Visit.
•3.Body mass index between 18.0 and 32.0 kg/m2 at Screening.
•4.Sparse, minimal, and fine hair on skin at application sites
•5.If a female of childbearing potential: must be either sexually inactive (abstinent) for at least 14 days prior to the first TDS application and remain sexually inactive throughout the study or be using an acceptable birth control method while within the study.
•6.A female of nonchildbearing potential: defined as either postmenopausal with amenorrhea for at least 1 year prior to Screening AND have an acceptable follicle-stimulating hormone serum levels or have official documentation of at least 1 sterilization procedures no less than 6 months prior to Screening.
•7.For a male: must agree to use an acceptable birth control method from Screening AND for at least 90 days following the last TDS removal

排除标准

•Key exclusion criteria include:
•1. History of any clinically significant medical or psychiatric condition or disease that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the subject by participation in the study
•2.History of alcoholism or drug abuse within the past 2 years prior to the first study product treatment, or current alcohol or drug abuse
•3.History of significant multiple, severe contact allergies, or has had 1 or more anaphylactic reactions, or is significantly intolerant to prescription or nonprescription drugs.
•4.Exhibiting symptoms suggestive of bladder outflow obstruction as assessed by the investigator.
•5.Potential for occupational exposure to anticholinesterase agents in the 5 weeks prior to Screening through the last TDS removal.
•6.Female subjects with a positive pregnancy test or who are lactating.
•7.History or presence of hairy skin on application sites that may potentially interfere with TDS adhesion and drug absorption. Clipping is permitted to remove fine or sparse hair. Subjects with heavy hair growth at the application site will not be eligible even with clipping.
•8.History or presence of significant skin damage, diffuse skin diseases, scars, tattoos on the application sites, or other skin disturbances or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug as deemed by the investigator to potentially interfere with drug absorption or irritation assessments; subjects with a spray tan applied less than 30 days prior to study dose are excluded.
•9.History or presence of significant dermatological disease or condition, such as atopy, psoriasis, vitiligo or conditions that are known to alter the skin appearance or physiologic response.
•10.History of or current consumption of high levels of caffeine (equivalent to 3 regular cups of coffee or 2 energy drinks, per day).
•11.Donation of blood or significant blood loss within 56 days prior to the first study product treatment.
•13.Plasma donation within 7 days prior to the first study product treatment.
•14.Use of donepezil HCl or related drugs within 60 days prior to the first study product treatment.
•15.Clinically significant depression symptoms or suicidal ideation or behavior.

研究者

发起方

Corium Inc.

相似试验

进行中（未招募）

1 期

A study to evaluate whether absorption of food while taking D-CURE has an impact on the level of vitamin D in blood

EUCTR2014-003779-48-BEABORATOIRES SMB S.A.88

已完成

1 期

A drug-drug interactions and food-effect study of S-600918 in healthy adult participantsRefractory chronic cough

JPRN-jRCT2031200413agata Tsutae42

进行中（未招募）

不适用

A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder once-daily (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®), Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) and a free combination of Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®) plus Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD) - Pharmacokinetics, safety and efficacy of Tiotropium/Salmeterol Inhalation PowderChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPD

EUCTR2007-000207-15-NLBoehringer Ingelheim bv50

进行中（未招募）

不适用

EUCTR2007-000207-15-BESCS Boehringer Ingelheim Comm.V50

已完成

不适用

A Randomized, prospective cross-over Study to Investigate the suitability and capability to swallow two oral placebo formulations in neonatesHealthy neonates.

DRKS00005609Klinik für Allgemeine Pädiatrie, Neonatologie und Kinderkardiologie151